Atlas Trials

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

Clinical trial NCT01927419 · COMPLETED

Trial details

NCT number
NCT01927419
Sponsor
Bristol-Myers Squibb
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Unresectable MelanomaMetastatic Melanoma
Start date
2013-08-23
Primary completion
2014-07-24
Enrollment
142

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.